Vizsgálati helyszín
Bekes Varmegyei Koezponti Korhaz
Bekescsaba, 5600, MagyarországEU-13 felzárkózó országMég nincs intézményhez kötve
- 20futó vizsgálat
- 16lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 36 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis17 vizsgálat
- 2. fázis16 vizsgálat
- 2/3. fázis3 vizsgálat
- Állapot
- Lezárult16 vizsgálat
- Toboroz12 vizsgálat
- Fut, nem toboroz7 vizsgálat
- Még nem toboroz1 vizsgálat
- Fő szponzor
- Merck Sharp & Dohme LLC4 vizsgálat
- Abivax S.A.3 vizsgálat
- Janssen Research & Development, LLC3 vizsgálat
- Amgen Inc.2 vizsgálat
- Boehringer Ingelheim2 vizsgálat
- és még 19
Futó vizsgálatok
Toboroz
Efficacy and safety of a combined therapy in the symptomatic treatment of diabetic sensorimotor polyneuropathy - a prospective, randomized, controlled, parallel group, double-blind, double-dummy 3-arm trial (ARIEL)
2025-521985-82-00· 2. fázis· Woerwag Pharma GmbH & Co. KG· Forrás
Meghívásos bevonás
Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD
NCT07652294· 2. fázis· Spyre Therapeutics, Inc.· Forrás
Toboroz
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
NCT07564414· 3. fázis· Novo Nordisk A/S· Forrás
Toboroz
LY4268989 (MORF-057) Co-Administered with Mirikizumab in Adults with Moderately to Severely Active Ulcerative Colitis: A Phase 2 Study
2025-522338-30-00· 2. fázis· Eli Lilly & Co.· Forrás
Toboroz
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
NCT07196722· 2/3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
NCT07196748· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008)
2024-518296-56-00· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
NCT07012395· 2. fázis· Spyre Therapeutics, Inc.· Forrás
Toboroz
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819878· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
NCT06651281· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
NCT06632457· 3. fázis· Boehringer Ingelheim· Forrás
Toboroz
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
NCT06456593· 2. fázis· Abivax S.A.· Forrás
Toboroz
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
NCT06632444· 3. fázis· Boehringer Ingelheim· Forrás
Fut, nem toboroz
Phase IIa Study Evaluating AZD7798 in Crohn's Disease
NCT06450197· 2. fázis· AstraZeneca· Forrás
Toboroz
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
NCT06226883· 2. fázis· Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
NCT06430801· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
ABTECT - Maintenance
NCT05535946· 3. fázis· Abivax S.A.· Forrás
Fut, nem toboroz
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
NCT03950232· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
NCT03466411· 2/3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
NCT03006068· 3. fázis· AbbVie· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Lezárult
A study to investigate the long-term safety, tolerability and efficacy of balinatunfib in participants with Crohn’s disease or ulcerative colitis
NCT07222189· 2. fázis· Sanofi-Aventis Recherche & Developpement· Forrás
Visszavonták
A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Maintenance of Healing in Participants With Healed Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)
NCT07313774· 3. fázis· Cinclus Pharma Holding AB· Forrás
Lezárult
A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)
NCT07037875· 3. fázis· Cinclus Pharma Holding AB· Forrás
Toboroz
Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)
NCT07048262· 2. fázis· CSL Behring· Forrás
Lezárult
A study to compare the effect of AVT16 and Entyvio® in subjects with moderate to severe active ulcerative colitis.
2023-507705-34-00· 3. fázis· Alvotech Swiss AG· Forrás
Lezárult
A study to investigate efficacy and safety of SAR441566 in patients with Crohn's disease.
NCT06637631· 2. fázis· Sanofi-Aventis Recherche & Developpement· Forrás
Fut, nem toboroz
Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06290934· 2. fázis· Gilead Sciences· Forrás
Lezárult
Long-term Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative Colitis
NCT05672199· 2. fázis· Amgen Inc.· Forrás
Fut, nem toboroz
Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis
NCT05588843· 2. fázis· Sanofi· Forrás
Lezárult
ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1
NCT05507203· 3. fázis· Abivax S.A.· Forrás
Lezárult
Safety and Efficacy of Efavaleukin Alfa in Subjects with Moderately to Severely Active Ulcerative Colitis
NCT04987307· 2. fázis· Amgen Inc.· Forrás
Lezárult
VTX002 versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis
2023-509233-39-00· 2. fázis· Oppilan Pharma Limited· Forrás
Lezárult
A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005)
NCT04996797· 2. fázis· Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)· Forrás
Lezárult
A Multicenter, Randomized, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn’s Disease
2024-513569-38-00· 2/3. fázis· Arena Pharmaceuticals Inc.· Forrás
Lezárult
Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)
NCT04029480· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Lezárult
Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn's Disease
2024-511553-22-00· 3. fázis· Celgene International II SARL· Forrás
Hibát jelzek